platoseedplatoseed
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Valink Therapeutics is developing next-generation bispecific antibody-drug conjugates (BsADCs) for cancer, using a proprietary platform to create more potent therapies that spare healthy tissue. Their approach, called V-Gate, aims to fine-tune targeting based on continuous levels of two disease-associated targets. They are advancing multiple oncology programs with a focus on reducing side effects and enabling new payloads.
Valink leverages the LiliumX platform, a discovery engine combining synthetic protein biology, high-throughput functional screening, and AI to identify bispecific ADCs. The company designs BsADCs with gating logic (V-Gate) that modulates binding to cancer cells based on two molecular targets, enabling more selective tumor targeting and potentially different payloads. They report several oncology programs in discovery and preclinical stages across indications such as CRC, NSCLC, and other solid tumors, with ongoing lead optimization and preclinical work.
Who it’s for: Biotech/pharma companies, cancer research institutions, and potential collaborators or licensors interested in next-generation BsADCs and novel discovery platforms.
Funding announcements (pre-seed/financing rounds), strategic alliance (2025), leadership appointments (2024)
Rhodes Scholar & DPhil Biochemistry from the University of Oxford
Pharma analyst with a background in protein engineering DPhil in Biochemistry from the University of Oxford
Formerly “SpyCombinator”, “LiliumX” · why startups rename →
Using protein coupling to build new therapies
Multi-targeted therapeutics to treat complex diseases
